BARROW HANLEY GLOBAL EQUITY TRUST

October 2025

FUND FACTS

Investment return objective: Aims to provide the trust with higher returns compared to the benchmark, while maintaining lower risk.

FUND BENEFITS

True traditional value portfolio concentrated in 50-70 stocks which focuses on undervalued companies with improving operating fundamentals identified by Barrow Hanley's screening process.

FUND RISKS

All investments carry risk and different strategies may carry different levels of risk. The relevant product disclosure statement or offer document for a fund should be considered before deciding whether to acquire or hold units in that fund. Your financial adviser can assist you in determining whether a fund is suited to your financial needs.

Benchmark: MSCI World Index (Measured in AUD)

Inception date: 6/05/2016

Delegated Investment Manager: Barrow Hanley Mewhinney & Strauss

APIR: ETL0434AU Management Fee: 0.99% p.a

Size of fund \$ 290.97 million as at 30/09/2025

 $\textbf{Suggested minimum investment period:} \ \ \textbf{Five years or longer}$

PORTFOLIO SECTORS



NET PERFORMANCE - Periods ending October 31, 2025


	Fund	Benchmark	Excess
1 month	0.9	3.3	-2.43
3 months	3.7	6.3	-2.64
FYTD	4.6	9.7	-5.03
1 year	15.7	22.6	-6.94
2 years	17.6	26.2	-8.59
3 years	15.6	21.3	-5.73
4 years	12.1	14.5	-2.41
5 years	16.5	17.8	-1.29
Since Inception	12.7	15.5	-2.82

Past performance is not indicative of future performance. Returns may differ due to different tax

TOP 5 STOCK HOLDINGS

	% of Portfolio
BANK OF NOVA SCOTIA	3.4%
STANDARD CHARTERED	2.9%
SANOFI SA	2.8%
BAE SYSTEMS PLC	2.3%
ENTERGY CORP	2 2%

PORTFOLIO REGIONS



During month of October, persistent themes driving market uncertainty such as policy ambiguity, geopolitical and trade tensions, and rapid shifts in economic data continued - with the added wrinkle of a long U.S. government shutdown. Despite these headwinds, global equity markets continued to push higher. The MSCI World Index rose 2.0% in October marking another month of positive returns. The S&P 500 outperformed developed markets other than Japan, as it was up 2.3%, supported by strength in growth-oriented sectors and reinforcing that the longer-term growth rally in the U.S. remains intact. The opposite is true in other developed markets, in which value is leading growth. Driven by the U.S., growth outperformed value, with the MSCI World Growth Index up 4.2% versus a decline of -0.5% for the MSCI World Value Index. On the year, the MSCI World Growth Index is outperforming its Value counterpart to the tune of 650 basis points. After a large relative decline in the first half of the year, the U.S. dollar (USD) has been range bound in total over the past couple of months, although it did recoup some losses in October against some currencies.

Sanofi positively contributed to relative performance during the month, supported by strong execution across its pharmaceutical and vaccine divisions. The company, a global pharmaceutical leader with specialties in immunology, oncology, rare diseases, and vaccines, maintained its full-year earnings guidance and demonstrated margin resilience. Notably, growth in Dupixent and Beyfortus helped offset weaker performance in other areas, with Dupixent continuing to expand across multiple indications. Management emphasized profitable growth for FY26, driven by volume gains, product mix improvements, and industrial restructuring.

LPL Financial Holdings Inc. positively contributed to relative performance during the month due to strong earnings and improved business fundamentals. The company, which provides investment and wealth management services to independent financial advisors, reported adjusted earnings per share that significantly exceeded expectations, driven by higher cash sweep fees and lower expenses. A key concern regarding advisor attrition at Commonwealth was alleviated, with 80% of assets already signed and a reaffirmed goal of 90%, reducing fears of mass migration to competitors. Net new assets and cash balances both grew in September, outpacing peers and supporting future growth.

BAE Systems plc detracted from relative performance during the month, despite securing notable new contracts and expanding their strategic footprint across Europe. BAE announced a £5.4B deal with Turkey for 20 new Eurofighters, which will be assembled in the UK, alongside a separate purchase of 24 second-hand jets from Qatar and Oman. While this order boosts BAE's Air division and restores momentum to its Warton assembly line, the broader European defense sector has been under pressure due to geopolitical uncertainty, including speculation around upcoming diplomatic meetings involving Trump and Putin.

Everest Group, Ltd. detracted from relative performance during the month due to an earnings miss and renewed investor concerns over reserve adequacy. The company, which provides insurance and reinsurance solutions globally, reported earnings per share of \$7.54, well below consensus expectations, driven by a \$478M adverse reserve charge. This charge followed a prior \$1.7B reserve addition in 4Q24, undermining management's previous assurances.

Looking ahead, the fourth quarter appears poised to extend the rally in the markets that began in April, supported by a shifting macroeconomic backdrop and the potential for broader market participation. After years of narrow leadership dominated by mega-cap technology and AI-driven names, cyclical sectors are showing signs of life, creating an interesting juxtaposition to the secular AI-fueled euphoria. While the AI boom seems durable, the significant divergence in performance over recent years suggests room for a relative catchup trade as expensive AI-exposed companies try to grow into current valuation levels. However, the positive data remains among a smaller group of more affluent consumers, as there is some evidence that the higher and lower ends of the income spectrum are experiencing

Equity Trustees Limited (Equity Trustees) ABN 46 004 031 298 | AFSL 240975 is the Responsible Entity for the Barrow Hanley Global Equity Trust (the Fund). Equity Trustees is a subsidiary of EQT Holdings Limited ABN 22 607 797 615, a publicly listed company on the Australian Securities Exchange (ASX: EQT). The Investment Manager for the Fund is Perpetual Investment Management Limited (Perpetual) ABN 18 000 866 535 | AFSL 234426. Perpetual has delegated the investment management of the Fund to Barrow, Hanley, Mewhinney & Strauss, LLC (BH). This information has been prepared by Perpetual to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Perpetual, BH, Equity Trustees nor any of their related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accept any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. The PDS can be obtained by calling 1800 022 033 or visiting our website www.perpetual.com.au. Barrow Hanley Global Equity Trust's Target Market Determination available here. A Target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.

MORE INFORMATION

Adviser Services 1800 062 725 Investor Services 1800 022 033 Email investments@perpetual.com.au www.perpetual.com.au

